drugset / Trial / NCT00084240

Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia

NCT00084240

Phase 2/3 Terminated 32 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective is to confirm the hypothesis that azithromycin (optimal dose once daily for three days) plus chloroquine is non-inferior to sulfadoxine-pyrimethamine plus chloroquine for the treatment of uncomplicated, symptomatic malaria due to P. falciparum.

Timeline

Start
2004-03
Primary completion
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule
Subject Sulfadoxine-pyrimethamine Small molecule
Background Chloroquine Small molecule